Keros Therapeutics
KROS
83 hedge funds and large institutions have $887M invested in Keros Therapeutics in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 31 increasing their positions, 24 reducing their positions, and 13 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 24
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
2% more funds holding
Funds holding: 81 → 83 (+2)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
8.01% less ownership
Funds ownership: 79.39% → 71.38% (-8%)
21% less capital invested
Capital invested by funds: $1.13B → $887M (-$242M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$21.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$18.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$18M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$9.98M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$6.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$132M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$31.7M |
| 3 |
VA
VR Adviser
New York
|
-$19M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.95M |
| 5 |
Goldman Sachs
New York
|
-$7.45M |
KROS Hedge Fund Activity: Q1 2021 in Review
83 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q1 2021, worth a combined $887M — down 21% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new KROS positions and 13 closed out — a net gain of 2 holders — while 31 added to existing stakes and 24 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $21.1M. The largest seller was RA Capital Management, exiting entirely with an estimated $132M sold.
- 83 institutional investors held Keros Therapeutics (KROS) as of Q1 2021, up from 81 in Q4 2020.
- Funds reported $887M of Keros Therapeutics stock for Q1 2021, down 21% quarter-over-quarter.
- 15 funds opened new Keros Therapeutics positions in Q1 2021 and 13 closed out, a net change of +2 holders.
- The largest Keros Therapeutics buyer in Q1 2021 was Consonance Capital Management, an estimated $21.1M added.
- The largest Keros Therapeutics seller in Q1 2021 was RA Capital Management, an estimated $132M sold.
Based on aggregated 13F filings for Q1 2021.